Degarelix Therapy for Prostate Cancer in a Real-world Setting

Experience From the German IQUO (Association for Uro-Oncological Quality Assurance) Firmagon Registry

Götz Geiges; Thomas Harms; Gerald Rodemer; Ralf Eckert; Frank König; Rolf Eichenauer; Jörg Schroder


BMC Urol. 2015;15(122) 

In This Article


This analysis of registry data showed degarelix to be effective and well tolerated in this real-world setting, confirming observations from controlled clinical studies. PSA-PFS appeared to be more favourable in comparison to earlier studies with other ADT treatments. Patients who had received prior HT appeared to have a significantly higher mortality risk than those who had not received prior HT.